Entry Point Capital, LLC Xenon Pharmaceuticals Inc. Transaction History
Entry Point Capital, LLC
- $206 Million
- Q1 2025
A detailed history of Entry Point Capital, LLC transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 8,872 shares of XENE stock, worth $278,846. This represents 0.14% of its overall portfolio holdings.
Number of Shares
8,872Holding current value
$278,846% of portfolio
0.14%Shares
3 transactions
Others Institutions Holding XENE
# of Institutions
219Shares Held
69.9MCall Options Held
444KPut Options Held
207K-
Avoro Capital Advisors LLC New York, NY5.74MShares$180 Million3.12% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.58MShares$144 Million1.68% of portfolio
-
Wellington Management Group LLP Boston, MA3.79MShares$119 Million0.03% of portfolio
-
Janus Henderson Group PLC London, X03.33MShares$105 Million0.06% of portfolio
-
Capital International Investors Los Angeles, CA3.09MShares$97.1 Million0.02% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $1.96B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...